Bridge City Capital’s ADMA Biologics ADMA Stock Holding History

Bridge City Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.66M	Buy	+265,689	New	+$2.46M	0.56%	77

Other funds holding ADMA

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return

Life Cycle Investment Partners London $23.6B AUM 38.44% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Bridge City Capital's ADMA Position: Q3 2026 in Review

Bridge City Capital opened a new position in ADMA Biologics (ADMA) in Q3 2026: 265,689 shares worth $2.66M. The stake represents 0.56% of the portfolio and ranks #77 among its holdings.

220 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

Bridge City Capital held 265,689 shares of ADMA Biologics worth $2.66M as of Q3 2026.
ADMA Biologics was a new Bridge City Capital position in Q3 2026.
ADMA Biologics made up 0.56% of Bridge City Capital's portfolio in Q3 2026, its #77 holding.
220 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Bridge City Capital's 13F filing for Q3 2026, filed 29 Oct 2026.